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Background. Systemic sclerosis (SSc) and localized scleroderma (LoS) are two different diseases that may share some features. We
evaluated the relationship between SSc and LoS in our case series of SSc patients. Methods. We analysed the clinical records of
330 SSc patients, in order to find the eventual occurrence of both the two diseases. Results. Eight (2.4%) female patients presented
both the two diagnoses in their clinical histories. Six developed LoS prior to SSc; in 4/6 cases, the presence of autoantibodies
was observed before SSc diagnosis. Overall, the median time interval between LoS and SSc diagnosis was 18 (range 0–156)
months. Conclusions. LoS and SSc are two distinct clinical entities that may coexist. Moreover, as anecdotally reported in pediatric
populations, we suggested the possible development of SSc in adult patients with LoS, particularly in presence of Raynaud’s
phenomenon or antinuclear antibodies before the SSc onset.
1. Introduction
Systemic sclerosis (SSc) is a connective tissue disease charac-
terized by different degrees of skin fibrosis and visceral organ
involvement.The etiology of SSc remains obscure; the disease
appears to be the result of a multistep and multifactorial
process, including immune system alterations, under the
influence of genetic and exogenous (toxic or infectious)
factors [1].
Morphea, also known as localized scleroderma (LoS), is
a distinctive inflammatory disease involving the skin and
the subcutaneous tissue, characterized by excessive collagen
deposition that ultimately leads to fibrosis. Differently from
SSc, Raynaud’s phenomenon, typical autoantibodies, and
visceral involvement are generally absent.
The incidence of LoS is around 0.3 to 3 cases per 100.000
inhabitants/year [2]. It affects commonly Caucasian women,
with a women/men ratio of 2–4/1, a similar prevalence in
children and adults with a peak in the fifth decade of life in
adults, whereas 90% of children are diagnosed between 2 and
14 years of age [3, 4].
Etiology of LoS is unknown, even if the probable trigger
is a vascular injury that culminates in increased collagen
production and decreased collagen destruction [5].
Plaque morphea lesions have an initial inflammatory (or
active) stage of erythematous to lilaceous dusky patches or
plaques; over time, the center becomes white and sclerotic,
and the borders take on a characteristic “lilaceous ring.”
When the active stage ends, white sclerotic plaques with
postinflammatory hyperpigmentation may be found. LoS
is classified according to clinical presentation: the most
widely used classification in literature is the “Mayo Clinic
Classification” [6, 7].
Plaque morphea is the most common presentation in
adults, unlike the linear morphea that is more common in
children and it often presents with fibrosis of underlying
tissues up to bone.The subcutaneous tissue and the muscular
fascia are targeted by the deep morphea. Finally, the general-
ized and the bullous morphea are rare clinical entities [3].
Though LoS is known as a dermatologic disease, it has
also been reported in literature the possibility of visceral
involvement, in the case of overlap with other autoimmune
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diseases or as possible evolution towards a systemic form; the
latter possibility was described anecdotally in pediatric cases
[8, 9].
Despite distinct clinical entities, SSc and LoS present
analogue histopathological findings [3–5]; furthermore, the
presence of autoantibodies or Raynaud’s phenomenon (RP)
could be reported also in LoS [3]. In this perspective they
might represent two extremities of the same spectrum of
disease.
The aim of our study was to retrospectively evaluate
a large SSc cohort in order to investigate the relationship
between SSc and LoS.
2. Patients and Methods
We retrospectively studied 330 patients fulfilling the
ACR/EULAR criteria for SSc [10] referring to our university-
based Rheumatology Unit from January 2003 to July 2017.
The eventual coexistence of LoS and SSc diagnosis was
searched for each patient in the medical records.The clinical,
laboratory, and instrumental features were available for all
patients, from the first visit at our referral center and
throughout the follow-up. In every patient, the description
of cutaneous sclerosis was registered, for the purpose of an
early SSc diagnosis or to document the progression of the
cutaneous sclerosis.
In case of LoS, the lesions were described as regards
number, site of localization, macroscopic aspects, and histo-
logical features obtained by skin biopsy, which is routinely
prescribed for new patients. In these cases, the referral to our
center was indicated by the dermatologist who first evaluated
the subjects.
Systemic symptoms and signs evocative for SSc, such as
presence of RP or acrocyanosis, telangiectasias or calcinosis,
visceral involvement such as interstitial lung disease, or
esophagus dyskinesia were always reported. Skin disorders
different from morphea were also included in the records.
Laboratory blood tests, including erythrocyte sedimen-
tation rate, c-reactive protein, blood cell counts, liver, kidney,
and thyroid function assessments, were routinely registered.
Moreover, spirometry, lung diffusion for carbon monoxide
test, chest high-resolution computed tomography, echocar-
diography, nailfold videocapillaroscopy, and esophagus X-ray
were carried out in all patients at the baseline and during the
follow-up, according to patients’ clinical conditions.
Possible exogenous toxic agents, such as cigarettes smok-
ing, occupational and environmental exposures, and the
eventual presence of comorbidities, were reported.
Finally, therapies administered for both localized and
systemic scleroderma were registered.
3. Results
In total, 8/330 (2.4%) SSc patients presented also LoS
(Table 1). Six SSc female patients (1.8%) had a clinical history
of LoS prior to SSc diagnosis (all limited SSc subtype). The
mean age at the time of LoS onset in these 6 cases was 43.5
years and the median time interval between Los and SSc
diagnosis was 18 (range 0–156) months.
Other 2 SSc patients (50 F, 70 F) developed LoS after 5
and 10 years of follow-up, at the trunk and left pretibial area,
respectively; both patients were anticentromere positive and
with limited skin SSc subset.
Skin biopsies confirmed the diagnosis of LoS, showing
nonspecific inflammatory infiltrate, collagen fiber deposition,
and dermis sclerosis.
In the 6 patients with LoS before SSc, RP preceded LoS
in 2 cases of 48 and 4 months, respectively; in the remaining
4 patients RP occurred after LoS onset, along with other SSc
systemic symptoms.
Cutaneous involvement was represented by patches of
skin sclerosis localized in limbs, trunk, or face; in one
case linear LoS was reported. A single lesion was found in
3/6 patients, while the remaining cases presented multiple
lesions.
Cutaneous limited SSc was diagnosed in all patients.
During the follow-up, 4/8 patients developed digital ulcers
(pitting scars and ulcers on calcinosis), 4/8 esophagopathy
confirmed with barium swallow test and only 1/8 interstitial
lung disease. No cardiac or renal involvements were reported;
moreover, 5/8 patients complained arthromyalgias in absence
of arthritis or myositis.
All patients underwent a nailfold videocapillaroscopy test
evidencing a typical SSc pattern [11] in 6/8 patients (active
pattern in 3, early pattern in 3 cases).
Serum antinuclear antibodies were detected in all
patients: 4 anticentromere, 2 antinucleolar, 1 anti-Scl70, and
1 ANA speckled. Of interest, the positivity of ANA was
observed in 4/6 LoS patients before the diagnosis of SSc.
No patient reported exposure to toxic substances or
cigarettes smoke; autoimmune thyroiditis was a comorbidity
in 2/8 patients.
Finally, no local treatment was employed for LoS, while
low dosage of systemic steroids was administered.
4. Discussion
In the present study, we retrospectively evaluated a large
cohort of SSc patients, in order to find the cases who
presented also LoS; eight patients (2.4%) were found.
LoS and SSc are two distinct clinical entities that may
share some features, such as the histopathological findings
in the skin and the possible presence of antinuclear autoanti-
bodies. In this perspective they might represent two ends of
a unique disease spectrum [8].
LoS and SSc cannot be differentiated by histopatho-
logical examination because they share the same aspects:
lymphocytic perivascular infiltration in the reticular dermis
and swollen endothelial cells in the early phase, followed
by thickened collagen bundles infiltrating the entire dermis
and extending into subcutaneous fat in the late phase,
with loss of eccrine glands and blood vessels, and “fat
trapping.” Therefore, skin biopsy does not allow making
differential diagnosis per se; conversely, the global evaluation
of the clinical picture is fundamental for the diagnosis. LoS
is characterized by the absence of sclerodactyly, RP, and
nailfold capillary changes; moreover, even if patients with
LoS commonly have nonspecific systemic symptoms, such
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Table 1: Summary of the patients of our series with LoS associated with SSc.
Number Age/sex Firstdiagnosis











(1) 26 F LoS
Morphea at right leg from 2
years; RP onset 4 years
before, new telangiectasias,
nondiagnostic alterations at





“early” SSc pattern at VC
Esophagopathy
(2) 60 F LoS
Morphea at the abdomen
from 2 years, ANoA,








(3) 33 F LoS
Recent onset of morphea at
right arm and face, ANA
speckled, SSc pattern at VC,
2 episodes of RP
7 SSc





(4) 69 F LoS
Recent onset of morphea at
dorsum, previous RP, puffy
hands, Scl70, DU, “active”
SSc pattern at VC
contemporary SSc - Sclerodermic face
(5) 50 F LoS
Recent onset of morphea at





12 SSc RP, sclerodactyly, ANoA,aspecific pattern at VC Esophagopathy
(6) 83 F LoS Morphea at dorsum from13 years, RP, ACA 156 SSc
RP, mild sclerodactyly,
ACA, “early” SSc pattern




(7) 70 F SSc RP, sclerodactyly, ACA, DU,Esophagopathy 120 LoS Left pretibial linear LoS -
(8) 50 F SSc
RP, sclerodactyly, ACA, DU,
“early” SSc pattern at VC,
melanodermia, calcinosis
60 LoS Morphea at trunk -
Legend. In the first 6 cases LoS was the first diagnosis made by a dermatologist; successively, these patients referred to ourRheumatology Unit because of the
suspect of an unrecognized SSc. After a variable period, SSc diagnosis was formulated in presence of a SSc-specific clinical picture. During the follow-ups,
eventual new features of the disease appeared; in the 7th and 8th case (italic rows) Los developed in the course of a definite SSc, in patients referring to our
Rheumatology Unit. The second diagnosis (LoS) was confirmed by the dermatologist.
as malaise, fatigue, arthralgias, and myalgias, as well as the
presence of autoantibodies, the typical features of SSc visceral
involvement are absent [3, 12].
Even if the course of LoS is usually benign, with slow
resolution of the skin lesions, there are data in literature
suggesting that LoS is not an exclusively cutaneous disease
[13].There is evidence of possible internal organs involvement
and association with other connective tissue disease, and the
evolution towards SSc was reported in pediatric population
[8, 9].
In this study, we documented the close onset of both LoS
and SSc in 3 patients and the apparent “evolution” from LoS
to SSc in other 3 cases. Nonetheless, the appearance of LoS
after SSc diagnosis (2 of our patients and others described
in literature) raises the hypothesis of mere coexistence of
LoS and SSc. The presence of RP and serum ANA positivity
or typical videocapillaroscopic alterations can be considered
“red flags” of SSc onset in patients with LoS, consistently
with what is reported in the literature regarding pediatric
population [8].
Interestingly, in our study, ANA positivity was reported
in 4/6 individuals before the diagnosis of SSc. Otherwise, the
presence of a scleroderma pattern at videocapillaroscopy was
a useful finding for the formulation of SSc diagnosis [1, 11].
The coexistence of SSc and LoS was already described
in 3.2–6.7% of SSc patients [14–19]. Toki et al. [16] found
9 cases (M/F 3/6) of LoS out of 135 SSc patients, and 6
were ANA negative. In the study by Maricq [14] only 1
case out of 12 developed SSc 6 months after the onset of
morphea, while the 2 diseases presented contemporary in
other 4 patients; in all these cases the limited SSc subset
was described. Chen et al. [15] described 8 patients with LoS
out of 220 SSc case series, and in 3 patients LoS preceded
the onset of SSc. Again, negative ANA were significantly
prevalent in the overlap subjects. Interestingly, considering
all the SSc/LoS cases described in the literature [14–19] plus
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Figure 1: Graphical representation of the LoS onset in 33 patients
(25 cases from the literature plus our 8 cases) concerning SSc onset
(coloured bars correspond to the time spans between LoS and SSc
beginnings). LoS may appear before or after SSc diagnosis, mainly
in a time period between −5 and +5 years from SSc onset (27/33,
81.8%). To note, in 5 patients LoS and SSc presented contemporarily
(“𝐶 = 6”).
our 8 patients, the LoS and SSc onsets are generally very close
(mean LoS-SSc difference time: 1.5 ± 5.7 years; Figure 1).
Indeed, the occurrence of two or more distinct autoimmune
disorders suggest the presence of a common autoimmunity-
prone background.
On the other hand, a prospective multicentre study per-
formed in four French academic dermatology departments
[20], including 76 patients with morphea and 101 age- and
sex-matched controls, did not find predictive signs for SSc
evolution in LoS patients, in comparison with controls.
Indeed, the authors concluded that SSc and LoS are not likely
as 2 entities belonging the same disease spectrum.
The main limit of our study is the small number of
patients who presented both LoS and SSc. However, the coex-
istence of these 2 disorders seems to be quite rare; therefore it
is difficult to recruit large case series. Therefore, the findings
of this preliminary study should be confirmed in multi-
centre large cohort-based surveys.
In conclusion, LoS and SSc are 2 distinct clinical entities
with autoimmune origin, and they are infrequently associated
with each other. The possible onset of SSc in LoS patients
should be considered, particularly in the cases that present
features suggestive for SSc development, such as RP, pres-
ence of SSc-specific autoantibodies, or videocapillaroscopic
abnormalities; in these cases, a careful clinical and laboratory
follow-up is recommended.
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